Jha Roshan, Cho Hye Young, Mushtaq Ameeq Ul, Lee Kiho, Kim Dae Gyu, Kim Sunghoon, Jeon Young Ho
College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Republic of Korea.
Medicinal Bioconvergence Research Center, Seoul National University, Seoul 08826, Republic of Korea; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Data Brief. 2017 Mar 10;11:533-536. doi: 10.1016/j.dib.2017.03.011. eCollection 2017 Apr.
AIMP2-DX2 is a splicing variant of AIMP2 protein which has been implicated in human lung cancer and chemoresistance of ovarian cancer (J.W. Choi, D.G. Kim, A.E. Lee, H.R. Kim, J.Y. Lee, N.H. Kwon, et al., 2011; J.W. Choi, J.W. Lee, J.K. Kim, H.K. Jeon, J.J. Choi, D.G. Kim, et al., 2012) [1,2]. We have shown, here, the data for the expression of AIMP2-DX2 protein in and optimization of the critical steps in purification of AIMP2-DX2. The data described here has been successfully used to get a maximum yield of highly pure AIMP2-DX2 for subsequent characterization of its biophysical property in: "Purification and biophysical characterization of the AIMP2-DX2 protein" (R. Jha, H.Y. Cho, A. Ul Mushtaq, K. Lee, D.G. Kim, S. Kim, et al., 2017) [3].
AIMP2-DX2是AIMP2蛋白的一种剪接变体，它与人类肺癌和卵巢癌的化疗耐药性有关（J.W. Choi、D.G. Kim、A.E. Lee、H.R. Kim、J.Y. Lee、N.H. Kwon等人，2011年；J.W. Choi、J.W. Lee、J.K. Kim、H.K. Jeon、J.J. Choi、D.G. Kim等人，2012年）[1,2]。在此，我们展示了AIMP2-DX2蛋白在[具体内容未提及]中的表达数据以及AIMP2-DX2纯化关键步骤的优化。此处描述的数据已成功用于获得高纯度AIMP2-DX2的最大产量，以便在《AIMP2-DX2蛋白的纯化与生物物理特性表征》（R. Jha、H.Y. Cho、A. Ul Mushtaq、K. Lee、D.G. Kim、S. Kim等人，2017年）[3]中对其生物物理特性进行后续表征。
